|
Kanim, Bae, et al. NASS 2003
Because
DBM comes from human tissue, there is the risk of disease transmission
and, of course, you must get the patient to sign an informed consent.
3.)
Infuse?
STRENGTH:
Can grow bone at rates comparable to autograft.
WEAKNESS:
Very expensive, limited FDA indications for use, significant side effect
profile (antibody formation, ectopic bone formation, contraindicated in
pregnant women, children under 18, and near tumors), should only be
used once in a patient’s lifetime.
4.) β
TCP?
STRENGTH:
Excellent osteoconductive matrix, no risk of disease transmission, safe,
proven efficacy, unlimited availability, multiple handling forms, FDA
approved for a wide variety of indications, convenient application, cost
effective.
WEAKNESS:
Not osteoinductive.
5.)
Platelet Jells?
STRENGTH:
Some efficacy in long bone use, available from patients own blood.
WEAKNESS:
Need to draw large quantities of blood, expensive centrifuge and
disposables needed, preparation time, no osteoconductive scaffold, poor
results in spine fusion, poor handling properties.
6.)
There is a unique new alternative:
Genex®
·
Excellent
osteoconductive matrix
·
No
risk of disease transmission
·
Safe, proven
efficacy
·
Unlimited
availability
·
Multiple
handling forms
·
FDA approved for a
wide variety of indications,
·
Convenient
application
·
Cost
effective
Genex®
represents a new concept in synthetic bone graft materials. It is
totally resorbable, fully synthetic bone graft material which can be
applied as an injectable paste to be contoured to the surgical site and
which sets in-situ at body temperature.
Key
Features and Benefits:
The
key properties of Genex® which distinguish the product from
other bone void fillers include:
·
Zeta Potential Control (ZPC™)
·
Smart Pores
·
Load Bearing Characteristics
Genex®
has Zeta Potential Control (ZPC™), a property unique to bone void
fillers which harnesses the key proteins involved in osteoblast
differentiation. To learn more about ZPC, click
here. |
